Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid diethylamide [LSD], dimethyltryptamine [DMT], mescaline) and atypical (ketamine, ibogaine, 5-MeO-DMT, 3,4-methylenedioxymethamphetamine) psychedelics for the treatment of addiction. Summary: We will start with an overview of the pharmacology and physiological and psychological properties of psychedelic substances from pre-clinical and clinical research. We will then provide an overview of evidence gathered by studies conducted in controlled research environments and naturalistic and ceremonial settings, while we identify the proposed therapeutic mechanisms of each psychedelic substance. Key Messages: Classic and atypical psychedelics show promise as therapeutic alternatives for the treatment of addiction, through the improvement of psychological and physiological symptoms of dependence. A more comprehensive understanding of the ancient and present-day knowledge of the therapeutic potential of psychedelics can facilitate hope for psychedelic therapeutics in the treatment of addiction, especially for individuals who have failed other conventional treatment methods.

It will never be known when our ancestors started to intentionally consume psychoactive substances for consciousness changing, but we can be certain that they encountered psilocybin-containing mushrooms in different regions around the globe [1]. What we can only presume were psilocybin mushrooms, have been depicted in cave art, petroglyphs, and stone sculptures, long before human writing [1]. Archaeological investigations provide evidence of psychedelic use in ritualistic settings, spiritual practices, and therapeutic purposes dating back to 8,500 BCE [1‒3].

Psychedelic substances became of scientific interest during the late 19th century with the synthesis of mescaline by Arthur Heffter [4, 5]. In the 1950s through to the early 1970s, there was an explosion of research using psychedelics with a great focus on their therapeutic potential for alcohol and drug addiction. Bill Wilson, founder of Alcoholics Anonymous, was the first person to bring psychedelics on the map for the treatment of addiction [6].

Despite this work and centuries of use within indigenous communities around the world, we have for the past 50 years seen a prohibition and stigmatisation of these substances, driven by the War on Drugs initiated by Nixon, that significantly restrained research on their effects and therapeutic properties [7]. Only in recent years have we seen the overturning of this prohibition with research using psychedelics, entering what has been called the “Psychedelic Renaissance”. For the purpose of this review, we use the term “classic psychedelics” to refer to psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT; ayahuasca), and mescaline that act as agonists at the 5HT2A receptor system and the term “atypical” psychedelics for ketamine, ibogaine, O-methyl-bufotenin (5-MeO-DMT), and 3,4-methyl​enedioxy​methamphetamine (MDMA).

Psychedelics are naturally occurring substances, but they can also be synthesised. A large amount of knowledge about psychedelic pharmacology and mechanisms has been derived from animal models. The head twitch response (HTR; paroxysmal rotational movement of the head) is one of the most common animal models for psychedelic activity [8, 9]. Recent pharmacological research using the HTR has pointed to the importance of the 5HT2A receptor in the action of classical psychedelics [8], with 5HT2A knock-out mice showing the absence of HTR following the administration of classic psychedelics [10]. In humans, the 5HT2A action of psychedelics contributes to their hallucinogenic effects [11, 12]. Aside from the 5HT2A receptor, other serotonin subtypes are involved, including the 5HT2B/C, 5HT1A, and also serotonin transporter [13]. Dopamine and noradrenaline receptors and transporters are also involved in the wider action of psychedelics [13].

The atypical psychedelic ketamine exerts its actions mainly via glutamatergic NMDA channel-blocking [14‒17] and ibogaine through the kappa and mu-opioid receptor partial agonism [15, 16]. MDMA is a serotonin, dopamine, and oxytocin releaser, with the release of oxytocin possibly explaining MDMA’s prosocial effects [13, 18]. 5-MeO-DMT probably has a similar action to classic psychedelics [13, 19].

Common physiological effects include increased heart rate, blood pressure, and body temperature which can remain high for several hours [20]. Nausea and vomiting, especially in high doses have also been observed [20].

The effects of psychedelics can be subjective and vary between individuals. Overall psychedelics can induce psychological alterations including changes in emotions, thoughts, mood, and perception (visual, auditory, tactile, olfactory, time, space) in the form of visual hallucinations and synaesthesia (stimulation of one sense causing the production of another sense), depersonalisation, and tactile sensation [12, 21, 22]. According to Pahnke, there are several characteristics of a psychedelic experience peak including, a “sense of unity, deeply felt positive mood, sense of sacredness, ineffability, and persisting positive changes in domains like attitudes and behaviour towards the self, others, life, and the experience itself” [23, 24].

Classic Psychedelics

Since the mid-late 20th century, a plethora of studies have been published on the use of classic psychedelics for the treatment of addiction [25]. Following the discovery of LSD in the 40s by Albert Hofmann, a spike in the interest of alcoholism treatment with LSD was seen [26]. In 2012, Krebs and Johansen published a meta-analysis of six randomised controlled trials, with a total of 536 treatment-seeking individuals, using a single dose of LSD to assist treatment programs of individual or group psychotherapy for alcoholism. Despite the varied LSD doses, differences in clinical interventions, and variations in the control conditions (low-dose LSD, d-amphetamine, ephedrine sulphate, or non-drug control) between the studies, the meta-analysis reported significant beneficial treatment effects on alcohol misuse following LSD at 3- and 6-month follow-up when compared with placebo (Table 1) [27]. The therapeutic potential of LSD paired with psychotherapy has also been researched for the treatment of heroin dependence (Table 2). Savage and McCabe found that the group assigned to LSD-assisted psychotherapy had significantly higher abstinence rates, with 33% abstinence at 12 months relative to the 5% seen in the control group [28]. Although 6 weeks of inpatient care provided only to the LSD groups could be a confounding factor in the results of this study, the outcomes are astounding for their time.

Table 1.

Summary of studies using classic and atypical psychedelics in non-ceremonial and ceremonial settings for alcohol use disorder

SubstanceAuthor(s)YearStudy characteristicsDrug and doseMain findings
a. Classic psychedelics (psilocybin, LSD) Krebs et al. [272012 Meta-analysis of randomised controlled trials LSD Significantly beneficial short-term (2–3-month post-treatment) and medium-term (6-month post-treatment) effects of LSD on alcohol misuse 
Six eligible trials Single dose 3/6 trials reported maintained abstinence from alcohol at short-term follow-up 
Total of 536 treatment-seeking participants (LSD, n = 325; placebo, n = 211) Doses range from 3 μg/kg (∼210 μg) to 800 μg 
Trials included treatment programs varying from individual or group psychotherapy, interpersonal skills training, and counselling on alcohol misuse and withdrawal 
 Bogenschutz et al. [292015 Single-group within-subject proof-of-concept study Psilocybin PHDD and percent of drinking days decreased post psilocybin (weeks 5–12) relative to baseline and weeks 1–4 (therapy only) 
Ten volunteers with alcohol dependence (DSM-IV) with at least two heavy drinking days in the past 30 days Session 1: 0.3 mg/kg Abstinence increased significantly following psilocybin administration relative to weeks 1–4 (therapy only) 
12-week MET with two psilocybin sessions (at 4 and 8 weeks) Session 2: 0.4 mg/kg Gains were largely maintained at follow-up to 36 weeks 
Intensity of acute effects in the first psilocybin session (week 4) strongly predicted change in 
1. Drinking during weeks 5–8 
2. Increases in abstinence 
3. Decreases in craving 
4. Changes in self-efficacy during week 5 
 Garcia-Romeu et al. [302019 Retrospective cross-sectional online survey study Psilocybin Following the reference psychedelic experience 
343 individuals fulfilling DSM-V criteria for past or current AUD LSD 1. 83% no longer met AUD criteria 
DMT/Ayahuasca 2. 28% endorsed psychedelic-associated changes in life priorities/values facilitating reduced alcohol misuse 
Moderate to high doses 3. 69% reported less severe withdrawal symptoms, particularly craving 
 Bogenschutz et al. [312022 Double-blind randomised clinical trial Psilocybin versus diphenhydramine (placebo) PHDD during the 32-week double-blind period was 9.7% (robust and sustained decreases in drinking) for the psilocybin group and 23.6% for the diphenhydramine group 
Ninety-five adults aged 25–65 years with a diagnosis of alcohol dependence (DSM-IV) and at least 4 heavy drinking days during the 30 days prior to screening Session 1: 25 mg/70 kg versus 50 mg Mean daily alcohol consumption (number of standard drinks per day) was also lower in the psilocybin group 
12 weeks of manualised psychotherapy (MET and cognitive behavioural therapy) and were randomly assigned to receive psilocybin or diphenhydramine twice (at 4 and 8 weeks) Session 2: 25–40 mg/70 kg versus 100 mg There were no serious adverse events among participants who received psilocybin 
Psilocybin administered in combination with psychotherapy produced robust decreases in percentage of heavy drinking days over and above those produced by active placebo and psychotherapy 
Participants who were treated with psilocybin were more likely than those receiving diphenhydramine to have no heavy drinking days 
b. Atypical psychedelics (ketamine, ibogaine, 5-MeO-DMT, MDMA) Krupitsky et al. [32] (no access to full paper) 1992 Non-randomised transpersonal therapy approaches with elements of aversive therapy in combination with one ketamine session Ketamine Ketamine-assisted therapy promoted higher levels of abstinence compared to the control group 
One hundred eighty-six alcohol-dependent individuals who either underwent ketamine assisted therapy or underwent traditional methods of therapy 2.5 mg/kg (im) 
 Krupitsky and Grinenko [33] (no access to full paper) 1997 Transpersonal assisted therapy in combination with one ketamine session Ketamine 65.8% abstinence (>1 year) in the ketamine group compared to 24% in the control group 
Two hundred eleven recently detoxified alcohol-dependent individuals who either underwent ketamine-assisted therapy or were treated as usual 2.5 mg/kg (im) 
 Barsuglia et al. [342018 Case report of a 31-year-old male military veteran with moderate AUD Ibogaine Alcohol cessation and reduced cravings at 5 days post-treatment 
Used ibogaine HCl on day 1 and vaporised 5-MeO-DMT on day 3 5-MeO-DMT Effects were sustained at 1 month 
Individual received SPECT neuroimaging before and 3 days after completion of the program Ibogaine HCl: 1,550 mg (17.9 mg/kg) Partial return to mild alcohol use at 2 months 
5-MeO-DMT: 5–7 mg (from 50 mg bufotoxin) 
 Das et al. [352019 Randomised single-blind placebo-controlled trial Ketamine In the ketamine administration immediately followed by MRM relative to the ketamine alone and MRM retrieval alone conditions, significant decreases were found in the following: 
Ninety beer-preferring non-treatment-seeking individuals with problematic alcohol use, no formal AUD diagnosis, and scores >8 in the AUDIT were randomised to one of three conditions Ketamine HCl and placebo concentrations were maintained at 350 ng/mL for 30 min 1. Drinking volume 
1. Ketamine and MRM retrieval with beer 2. Drinking enjoyment 
2. Ketamine alone with orange juice 3. Urge to drink a beer placed in front of them 
3. Placebo and MRM retrieval 4. General alcohol consumption (beer, wine, or spirits) 
 Dakwar et al. [362020 Randomised midazolam-controlled pilot study Ketamine Ketamine relative to midazolam significantly 
Forty treatment-seeking alcohol-dependent (DSM-IV) individuals Ketamine HCl: 0.71 mg/kg (iv) 1. Increased the likelihood of abstinence 
5-week MET and were randomly assigned to receive ketamine or active control midazolam during week 2 Midazolam) active control): 0.025 mg/kg 2. Delayed the time to relapse 
3. Reduced the likelihood of heavy drinking days 
 Sessa et al. [372021 Open-label safety and tolerability proof-of-concept study MDMA MDMA treatment was safe and tolerated by all participant 
Fourteen detoxification-seeking individuals with AUD (DSM-V) completed a community alcohol detoxification and received an 8-week/10-session course of recovery-based therapy with MDMA at sessions 3 and 7 Total of 187.5 mg in each session: 125 mg initial dose and 62.5 mg booster dose on same day Psychosocial functioning improved across the cohort 
At 9-month post-detox, there was a decrease in average units of alcohol consumption by participants from 130.6 units/week pre-detox to 18.7 units/week post-detox 
 Grabski et al. [382022 Double-blind placebo-controlled phase II clinical trial Ketamine Significantly greater number of abstinence days from alcohol in the ketamine relative to the placebo group at 3- and 6-month follow-up (pooled across therapy conditions) 
Ninety-six recently detoxified individuals with AUD (DSM-IV/V) were randomised to one of four conditions Ketamine: 0.8 mg/kg (iv) No difference in relapse rates between the ketamine and the placebo groups 
1. Three weekly ketamine (active) infusions plus psychological therapy (MBRP) (active) Placebo: 0.9% saline (iv) 
2. Three ketamine (active) infusions plus alcohol education (control) 
3. Three saline infusions (control) plus psychological therapy (active) 
4. Three saline infusions (control) plus alcohol education (control) 
c. Ceremonial psychedelic use (mescaline-containing Peyote cactus, DMT-containing Ayahuasca brew) Albaugh and Anderson [391974 American Indians from the Cheyenne and Arapaho tribes with alcohol dependence Peyote cactus Discussion about alcoholism and emotions during the NAC ceremonies was helpful in overcoming their alcohol dependence 
30-day inpatient programme at the Clinton Indian Hospital in Oklahoma Peyote buttons (average: 11 buttons, 45 mg mescaline each) Carry-over effect of 7–10 days post peyote of openness and willingness to communicate 
Therapeutic approach: group meetings, cultural and occupational therapy, and taking part in meetings at the Native American Church (NAC), with and without peyote/mescaline Average mescaline: 500 mg 
 Doering-Silveira et al. [402005 Cross-sectional study Ayahuasca Significantly lower alcohol consumption in 
Eighty-four ayahuasca consuming and national normative sample of adolescents (15–19 years; Brazil) N/A 1. Last-month 
Ayahuasca-consuming adolescents (ritual context; n = 41) were selected from three syncretic churches Uniao do Vegetal (UDV) 2. Last-year 
Focussing on general drug and alcohol consumption (no addiction) 
Drunk ayahuasca within a ritual context at least 24 times during the last 2 years prior to the assessment 
World Health Organisation (WHO) criteria for psychoactive drug use 
SubstanceAuthor(s)YearStudy characteristicsDrug and doseMain findings
a. Classic psychedelics (psilocybin, LSD) Krebs et al. [272012 Meta-analysis of randomised controlled trials LSD Significantly beneficial short-term (2–3-month post-treatment) and medium-term (6-month post-treatment) effects of LSD on alcohol misuse 
Six eligible trials Single dose 3/6 trials reported maintained abstinence from alcohol at short-term follow-up 
Total of 536 treatment-seeking participants (LSD, n = 325; placebo, n = 211) Doses range from 3 μg/kg (∼210 μg) to 800 μg 
Trials included treatment programs varying from individual or group psychotherapy, interpersonal skills training, and counselling on alcohol misuse and withdrawal 
 Bogenschutz et al. [292015 Single-group within-subject proof-of-concept study Psilocybin PHDD and percent of drinking days decreased post psilocybin (weeks 5–12) relative to baseline and weeks 1–4 (therapy only) 
Ten volunteers with alcohol dependence (DSM-IV) with at least two heavy drinking days in the past 30 days Session 1: 0.3 mg/kg Abstinence increased significantly following psilocybin administration relative to weeks 1–4 (therapy only) 
12-week MET with two psilocybin sessions (at 4 and 8 weeks) Session 2: 0.4 mg/kg Gains were largely maintained at follow-up to 36 weeks 
Intensity of acute effects in the first psilocybin session (week 4) strongly predicted change in 
1. Drinking during weeks 5–8 
2. Increases in abstinence 
3. Decreases in craving 
4. Changes in self-efficacy during week 5 
 Garcia-Romeu et al. [302019 Retrospective cross-sectional online survey study Psilocybin Following the reference psychedelic experience 
343 individuals fulfilling DSM-V criteria for past or current AUD LSD 1. 83% no longer met AUD criteria 
DMT/Ayahuasca 2. 28% endorsed psychedelic-associated changes in life priorities/values facilitating reduced alcohol misuse 
Moderate to high doses 3. 69% reported less severe withdrawal symptoms, particularly craving 
 Bogenschutz et al. [312022 Double-blind randomised clinical trial Psilocybin versus diphenhydramine (placebo) PHDD during the 32-week double-blind period was 9.7% (robust and sustained decreases in drinking) for the psilocybin group and 23.6% for the diphenhydramine group 
Ninety-five adults aged 25–65 years with a diagnosis of alcohol dependence (DSM-IV) and at least 4 heavy drinking days during the 30 days prior to screening Session 1: 25 mg/70 kg versus 50 mg Mean daily alcohol consumption (number of standard drinks per day) was also lower in the psilocybin group 
12 weeks of manualised psychotherapy (MET and cognitive behavioural therapy) and were randomly assigned to receive psilocybin or diphenhydramine twice (at 4 and 8 weeks) Session 2: 25–40 mg/70 kg versus 100 mg There were no serious adverse events among participants who received psilocybin 
Psilocybin administered in combination with psychotherapy produced robust decreases in percentage of heavy drinking days over and above those produced by active placebo and psychotherapy 
Participants who were treated with psilocybin were more likely than those receiving diphenhydramine to have no heavy drinking days 
b. Atypical psychedelics (ketamine, ibogaine, 5-MeO-DMT, MDMA) Krupitsky et al. [32] (no access to full paper) 1992 Non-randomised transpersonal therapy approaches with elements of aversive therapy in combination with one ketamine session Ketamine Ketamine-assisted therapy promoted higher levels of abstinence compared to the control group 
One hundred eighty-six alcohol-dependent individuals who either underwent ketamine assisted therapy or underwent traditional methods of therapy 2.5 mg/kg (im) 
 Krupitsky and Grinenko [33] (no access to full paper) 1997 Transpersonal assisted therapy in combination with one ketamine session Ketamine 65.8% abstinence (>1 year) in the ketamine group compared to 24% in the control group 
Two hundred eleven recently detoxified alcohol-dependent individuals who either underwent ketamine-assisted therapy or were treated as usual 2.5 mg/kg (im) 
 Barsuglia et al. [342018 Case report of a 31-year-old male military veteran with moderate AUD Ibogaine Alcohol cessation and reduced cravings at 5 days post-treatment 
Used ibogaine HCl on day 1 and vaporised 5-MeO-DMT on day 3 5-MeO-DMT Effects were sustained at 1 month 
Individual received SPECT neuroimaging before and 3 days after completion of the program Ibogaine HCl: 1,550 mg (17.9 mg/kg) Partial return to mild alcohol use at 2 months 
5-MeO-DMT: 5–7 mg (from 50 mg bufotoxin) 
 Das et al. [352019 Randomised single-blind placebo-controlled trial Ketamine In the ketamine administration immediately followed by MRM relative to the ketamine alone and MRM retrieval alone conditions, significant decreases were found in the following: 
Ninety beer-preferring non-treatment-seeking individuals with problematic alcohol use, no formal AUD diagnosis, and scores >8 in the AUDIT were randomised to one of three conditions Ketamine HCl and placebo concentrations were maintained at 350 ng/mL for 30 min 1. Drinking volume 
1. Ketamine and MRM retrieval with beer 2. Drinking enjoyment 
2. Ketamine alone with orange juice 3. Urge to drink a beer placed in front of them 
3. Placebo and MRM retrieval 4. General alcohol consumption (beer, wine, or spirits) 
 Dakwar et al. [362020 Randomised midazolam-controlled pilot study Ketamine Ketamine relative to midazolam significantly 
Forty treatment-seeking alcohol-dependent (DSM-IV) individuals Ketamine HCl: 0.71 mg/kg (iv) 1. Increased the likelihood of abstinence 
5-week MET and were randomly assigned to receive ketamine or active control midazolam during week 2 Midazolam) active control): 0.025 mg/kg 2. Delayed the time to relapse 
3. Reduced the likelihood of heavy drinking days 
 Sessa et al. [372021 Open-label safety and tolerability proof-of-concept study MDMA MDMA treatment was safe and tolerated by all participant 
Fourteen detoxification-seeking individuals with AUD (DSM-V) completed a community alcohol detoxification and received an 8-week/10-session course of recovery-based therapy with MDMA at sessions 3 and 7 Total of 187.5 mg in each session: 125 mg initial dose and 62.5 mg booster dose on same day Psychosocial functioning improved across the cohort 
At 9-month post-detox, there was a decrease in average units of alcohol consumption by participants from 130.6 units/week pre-detox to 18.7 units/week post-detox 
 Grabski et al. [382022 Double-blind placebo-controlled phase II clinical trial Ketamine Significantly greater number of abstinence days from alcohol in the ketamine relative to the placebo group at 3- and 6-month follow-up (pooled across therapy conditions) 
Ninety-six recently detoxified individuals with AUD (DSM-IV/V) were randomised to one of four conditions Ketamine: 0.8 mg/kg (iv) No difference in relapse rates between the ketamine and the placebo groups 
1. Three weekly ketamine (active) infusions plus psychological therapy (MBRP) (active) Placebo: 0.9% saline (iv) 
2. Three ketamine (active) infusions plus alcohol education (control) 
3. Three saline infusions (control) plus psychological therapy (active) 
4. Three saline infusions (control) plus alcohol education (control) 
c. Ceremonial psychedelic use (mescaline-containing Peyote cactus, DMT-containing Ayahuasca brew) Albaugh and Anderson [391974 American Indians from the Cheyenne and Arapaho tribes with alcohol dependence Peyote cactus Discussion about alcoholism and emotions during the NAC ceremonies was helpful in overcoming their alcohol dependence 
30-day inpatient programme at the Clinton Indian Hospital in Oklahoma Peyote buttons (average: 11 buttons, 45 mg mescaline each) Carry-over effect of 7–10 days post peyote of openness and willingness to communicate 
Therapeutic approach: group meetings, cultural and occupational therapy, and taking part in meetings at the Native American Church (NAC), with and without peyote/mescaline Average mescaline: 500 mg 
 Doering-Silveira et al. [402005 Cross-sectional study Ayahuasca Significantly lower alcohol consumption in 
Eighty-four ayahuasca consuming and national normative sample of adolescents (15–19 years; Brazil) N/A 1. Last-month 
Ayahuasca-consuming adolescents (ritual context; n = 41) were selected from three syncretic churches Uniao do Vegetal (UDV) 2. Last-year 
Focussing on general drug and alcohol consumption (no addiction) 
Drunk ayahuasca within a ritual context at least 24 times during the last 2 years prior to the assessment 
World Health Organisation (WHO) criteria for psychoactive drug use 

ASI, Addiction Severity Index; AUD, alcohol use disorder; AUDIT, Alcohol Use Disorders Identification Test; DMT, N, N-dimethyltryptamine; DSM, Diagnostic and Statistical Manual of Mental Disorders; HCl, hydrochloride; LSD, lysergic acid diethylamide; MDMA, 3,4-methyl​enedioxy​methamphetamine; MET, motivational enhancement therapy; MRM, Maladaptive reward memory; NAC, Native American Church; PHDD, percentage of heavy drinking days; UDV, Uniao do Vegetal (churches); WHO, World Health Organisation; 5-MeO-DMT, O-methyl-bufotenin; MBRP, mindfulness-based relapse prevention.

Table 2.

Summary of studies using classic and atypical psychedelics for opioid use disorder

SubstanceAuthor(s)YearStudy characteristicsDoseMain findings
a. Ibogaine Alper et al. [41] (no access to full paper) 1999 Open-label case series 19.3±6.9 mg/kg Within 24 h and throughout 72 h, 25/33 cases reported 
Thirty-three opioid-dependent individuals (DSM-IV) 1. Resolution of opioid withdrawal 
2. No drug-seeking behaviour 
Other symptom improvements include 
1. Drug-seeking behaviour without withdrawal signs (n = 4) 
2. Drug abstinence with attenuated withdrawal signs (n = 2) 
 Mash et al. [422001 Observational study Ibogaine HCl: 800 mg (10 mg/kg) At 12 h, 24 h, and 36 h post-ibogaine treatment, significant reduction in withdrawal symptoms assessed by the “Objective Opiate Withdrawal Scale” and “Opiate-Symptom Checklist” 
Thirty-two opioid-dependent (DSM-IV) individuals seeking heroin or methadone detoxification 
The treatment program offered motivational counselling and referral to aftercare programs and community support groups (twelve-step programs) 
 Noller et al. [432017 Observational study Ibogaine HCl: 31.4±7.6 mg At 12-month follow-up, there was significant 
Fourteen treatment-seeking opioid dependence (DSM-IV) individuals 1. Attenuation of withdrawal symptoms (ASI Lite) 
2. Decrease in drug craving and use (Subjective Opioid Withdrawal Scale) 
3. Decrease in depressive symptoms 
 Brown et al. [442018 Observational study Ibogaine HCl: 1,540±920 mg Significant reduction in opioid withdrawal between pre- and post-treatment with ibogaine 
Thirty treatment-seeking opioid-dependent individuals (DSM-IV) Relative to baseline, at 3-, 6-, 9-, 12-month follow-ups, significant improvement in Drug Use, Family/Social Status, and Legal Status (ASI Lite) 
 Malcolm et al. [452018 Observational study Ibogaine HCl: 18–20 mg/kg At 48 h post-ibogaine treatment, relative to baseline 
Fifty opioid-dependent individuals (DSM-V) with prior ibogaine treatment experience for their opioid dependence For participants who experience post-acute withdrawal symptoms at 72 h post-ibogaine administration, an additional 1–5 mg/kg ibogaine HCl was administrated 1. 78% of patients did not experience clinical signs of opioid withdrawal 
Three-part treatment program, including coaching, ibogaine administration, a week-long ibogaine detoxification treatment, and optional residential aftercare program or weekly recovery coaching 2. 79% reported minimal cravings for opioids 
3. 68% reported mild subjective withdrawal symptoms 
b. Ketamine Krupitsky et al. [462002 Double-blind active-placebo-controlled randomised clinical trial Hallucinogenic/high dose: 2.0 mg/kg (im) High dose of ketamine relative to the low dose showed significantly 
Seventy detoxified heroin dependent patients Non-hallucinogenic/low dose: 0.2 mg/kg (im) 1. Greater rate of abstinence within the first 2 years of follow-up 
Existentially oriented psychotherapy in combination with one ketamine session (hallucinogenic dose or sub-hallucinogenic dose active placebo) 2. Greater and longer-lasting reduction in heroin craving 
3. Greater positive change in nonverbal unconscious emotional attitudes 
4. Lower relapse rates 
c. Classic psychedelics Savage and McCabe [281973 Seventy-eight heroin dependent inmates randomly assigned to either a single dose of LSD and psychotherapy or to an outpatient program with weekly psychotherapy sessions (control) LSD, 300–350 μg Significantly higher abstinent rates in the LSD-assisted psychotherapy group relative to the control group at 6- and 12-month follow-ups 
At 12-month follow-up, the LSD group presented with 33% abstinence rates relative to the 5% rate of the control group 
Pisano et al. [472017 Association study Psilocybin Psychedelic drug use is associated with 
44,000 responders with history of illicit opioid user who completed the National Survey on Drug Use and Health (NSDUH) from 2008 to 2013 and met NSDUH’s dependence criteria LSD 1. 27% reduced risk of past-year opioid dependence 
Mescaline/Peyote/San Pedro 2. 40% reduced risk of past-year opioid abuse 
DMT/Ayahuasca 
Dose N/A 
Argento et al. [482022 Prospective cohort survey study Classic psychedelics Significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29–0.70) 
Cohorts of community-recruited people who use drugs (PWUD) in Vancouver, Canada Dose N/A 
Among 3,813 PWUD at baseline, 1,093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past 6 months 
SubstanceAuthor(s)YearStudy characteristicsDoseMain findings
a. Ibogaine Alper et al. [41] (no access to full paper) 1999 Open-label case series 19.3±6.9 mg/kg Within 24 h and throughout 72 h, 25/33 cases reported 
Thirty-three opioid-dependent individuals (DSM-IV) 1. Resolution of opioid withdrawal 
2. No drug-seeking behaviour 
Other symptom improvements include 
1. Drug-seeking behaviour without withdrawal signs (n = 4) 
2. Drug abstinence with attenuated withdrawal signs (n = 2) 
 Mash et al. [422001 Observational study Ibogaine HCl: 800 mg (10 mg/kg) At 12 h, 24 h, and 36 h post-ibogaine treatment, significant reduction in withdrawal symptoms assessed by the “Objective Opiate Withdrawal Scale” and “Opiate-Symptom Checklist” 
Thirty-two opioid-dependent (DSM-IV) individuals seeking heroin or methadone detoxification 
The treatment program offered motivational counselling and referral to aftercare programs and community support groups (twelve-step programs) 
 Noller et al. [432017 Observational study Ibogaine HCl: 31.4±7.6 mg At 12-month follow-up, there was significant 
Fourteen treatment-seeking opioid dependence (DSM-IV) individuals 1. Attenuation of withdrawal symptoms (ASI Lite) 
2. Decrease in drug craving and use (Subjective Opioid Withdrawal Scale) 
3. Decrease in depressive symptoms 
 Brown et al. [442018 Observational study Ibogaine HCl: 1,540±920 mg Significant reduction in opioid withdrawal between pre- and post-treatment with ibogaine 
Thirty treatment-seeking opioid-dependent individuals (DSM-IV) Relative to baseline, at 3-, 6-, 9-, 12-month follow-ups, significant improvement in Drug Use, Family/Social Status, and Legal Status (ASI Lite) 
 Malcolm et al. [452018 Observational study Ibogaine HCl: 18–20 mg/kg At 48 h post-ibogaine treatment, relative to baseline 
Fifty opioid-dependent individuals (DSM-V) with prior ibogaine treatment experience for their opioid dependence For participants who experience post-acute withdrawal symptoms at 72 h post-ibogaine administration, an additional 1–5 mg/kg ibogaine HCl was administrated 1. 78% of patients did not experience clinical signs of opioid withdrawal 
Three-part treatment program, including coaching, ibogaine administration, a week-long ibogaine detoxification treatment, and optional residential aftercare program or weekly recovery coaching 2. 79% reported minimal cravings for opioids 
3. 68% reported mild subjective withdrawal symptoms 
b. Ketamine Krupitsky et al. [462002 Double-blind active-placebo-controlled randomised clinical trial Hallucinogenic/high dose: 2.0 mg/kg (im) High dose of ketamine relative to the low dose showed significantly 
Seventy detoxified heroin dependent patients Non-hallucinogenic/low dose: 0.2 mg/kg (im) 1. Greater rate of abstinence within the first 2 years of follow-up 
Existentially oriented psychotherapy in combination with one ketamine session (hallucinogenic dose or sub-hallucinogenic dose active placebo) 2. Greater and longer-lasting reduction in heroin craving 
3. Greater positive change in nonverbal unconscious emotional attitudes 
4. Lower relapse rates 
c. Classic psychedelics Savage and McCabe [281973 Seventy-eight heroin dependent inmates randomly assigned to either a single dose of LSD and psychotherapy or to an outpatient program with weekly psychotherapy sessions (control) LSD, 300–350 μg Significantly higher abstinent rates in the LSD-assisted psychotherapy group relative to the control group at 6- and 12-month follow-ups 
At 12-month follow-up, the LSD group presented with 33% abstinence rates relative to the 5% rate of the control group 
Pisano et al. [472017 Association study Psilocybin Psychedelic drug use is associated with 
44,000 responders with history of illicit opioid user who completed the National Survey on Drug Use and Health (NSDUH) from 2008 to 2013 and met NSDUH’s dependence criteria LSD 1. 27% reduced risk of past-year opioid dependence 
Mescaline/Peyote/San Pedro 2. 40% reduced risk of past-year opioid abuse 
DMT/Ayahuasca 
Dose N/A 
Argento et al. [482022 Prospective cohort survey study Classic psychedelics Significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29–0.70) 
Cohorts of community-recruited people who use drugs (PWUD) in Vancouver, Canada Dose N/A 
Among 3,813 PWUD at baseline, 1,093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past 6 months 

ASI, Addiction Severity Index; DMT, N, N-dimethyltryptamine; DSM, Diagnostic and Statistical Manual of Mental Disorders; HCl, hydrochloride; LSD, lysergic acid diethylamide; NSDUH, National Survey on Drug Use and Health; PWUD, people who use drugs.

Fast forward to the 21st century, psilocybin has been used in addiction treatment research, especially for alcohol and tobacco. Psilocybin is found in several mushroom species, with the most known being Psilocybe cubensis [49]. The indigenous communities of Mexico have a long tradition of psilocybin-containing mushroom ceremonial use. In 1957, the Mazatec Shaman María Sabina through Gordon Wasson brought the traditional ritual knowledge to the West [50], paving the way for its use in modern-day psychiatry. In 2015 and 2022, Bogenschutz and his team conducted a pilot study and a phase II randomised double-blind clinical trial looking into the therapeutic potential of two psilocybin doses in combination with 12 weeks of motivational enhancement therapy for the treatment of alcoholism. They found a significant increase in abstinence and a decrease in the percentage of drinking days and heavy drinking days following psilocybin and psychotherapy relative to the control condition (Table 1, 3) [29, 31]. Limitations of sample size and lack of a control group in the pilot study were overcome in the phase II clinical trial, but challenges with blinding remained, as diphenhydramine, the placebo used in the trial, was ineffective in maintaining the blind.

Table 3.

Number of treatments needed for each psychedelic (classic and atypical) substance

DrugNumber of treatment sessions
aPsilocybin 
LSD 
Ketamine 1–3 
MDMA 
bIbogaine 1–2 
DrugNumber of treatment sessions
aPsilocybin 
LSD 
Ketamine 1–3 
MDMA 
bIbogaine 1–2 

aPsilocybin: 3rd dose is optional.

bIbogaine: up to ×9 times, most common 1–2 times [60].

Johnson et al. [51] and Garcia-Romeu et al. with a similar concept approached tobacco use disorder with two psilocybin doses plus a combination of cognitive behavioural therapy and mindfulness training for smoking cessation. At the 6-month follow-up, 80% were abstinent, with 67% remaining abstinent at the 12-month follow-up and 60% at the 30-month follow-up (Table 4) [52]. They also found that abstinent individuals scored higher in the psilocybin-occasioned mystical experience relative to participants still smoking at 6 months, with a “complete” mystical experience significantly correlating with smoking cessation outcomes (Table 4) [53]. The results of these studies should be interpreted with caution given the small sample size and open-label design. Potential psychological mechanisms for the therapeutic effects of psilocybin and other classic psychedelics may rely on their ability to elicit mystical, transcendent, or peak experiences [30, 51‒53]. Other proposed mechanisms attribute their therapeutic potential to their ability to reduce craving and anxiety, which are key components of relapse [53, 54] and to their ability to increase motivation and self-efficacy [53].

Table 4.

Summary of studies using psilocybin for tobacco use disorder

SubstanceAuthor(s)YearStudy characteristicsDoseMain findings
a. Psilocybin Johnson et al. [512014 Open-label pilot study Moderate: 20 mg/70 kg 80% self-reported quitting smoking (biologically verified smoking abstinence) throughout the weeks of active treatment 
Fifteen nicotine-dependent smokers with previous unsuccessful quit attempts, still desiring to quit High: 30 mg/70 kg 80% were abstinent at 6-month follow-up 
15-week smoking cessation CBT with three psilocybin sessions (at 5, 7, and 13 optional weeks) Significant reductions in self-reported daily smoking from first psilocybin session to 6-month follow-up 
Significantly decreased craving 
At 12-month follow-up, 10/12 (67%) returning participants were smoking abstinent (Johnson et al. 2017) 
At long-term follow-up (average 30-months), 9/12 (60%) were smoking abstinent (Johnson et al. 2017) 
 Garcia-Romeu et al. [532015 Open-label pilot study Session 1 (moderate): 20 mg/70 kg At 6-month follow-up 80% were abstinent 
Fifteen smokers with previous unsuccessful quit attempts, still desiring to quit Session 2 (high): 30 mg/70 kg The abstinent individuals scored significantly higher on a measure of psilocybin-occasioned mystical experience relative to participants still smoking at 6 months 
15-week smoking cessation treatment intervention (CBT and mindfulness training) with two psilocybin session at week 5 and 7 and an optional high third dose at week 13 60% met criteria for “complete” mystical experience which was significantly correlated with smoking cessation outcome 
 Johnson et al. [522017 Retrospective cross-sectional anonymous online survey Psilocybin 38% reported continuous smoking cessation after psychedelic use (Quit group) 
358 individuals who reported having quit or reduced smoking after ingesting a psychedelic in a non-laboratory setting LSD 74.5% of the “Quit group” reported >2 years of abstinence 
Mescaline 28% reported a persisting reduction in smoking (Reduce group) 
DMT/Ayahuasca 62% of the “Reduce group” reported >2 years reduction in smoking 
Dose N/A 34% reported temporary reduction in their smoking before returning to baseline smoking level (Relapse group) 
Participants across all groups reported less severe affective withdrawal symptoms (e.g., depression, craving) after psychedelic use compared with previous quit attempts 
Participants in the “Relapse group” rated the reference psychedelic experience as significantly less personally meaningful than those in the “Quit group” 
SubstanceAuthor(s)YearStudy characteristicsDoseMain findings
a. Psilocybin Johnson et al. [512014 Open-label pilot study Moderate: 20 mg/70 kg 80% self-reported quitting smoking (biologically verified smoking abstinence) throughout the weeks of active treatment 
Fifteen nicotine-dependent smokers with previous unsuccessful quit attempts, still desiring to quit High: 30 mg/70 kg 80% were abstinent at 6-month follow-up 
15-week smoking cessation CBT with three psilocybin sessions (at 5, 7, and 13 optional weeks) Significant reductions in self-reported daily smoking from first psilocybin session to 6-month follow-up 
Significantly decreased craving 
At 12-month follow-up, 10/12 (67%) returning participants were smoking abstinent (Johnson et al. 2017) 
At long-term follow-up (average 30-months), 9/12 (60%) were smoking abstinent (Johnson et al. 2017) 
 Garcia-Romeu et al. [532015 Open-label pilot study Session 1 (moderate): 20 mg/70 kg At 6-month follow-up 80% were abstinent 
Fifteen smokers with previous unsuccessful quit attempts, still desiring to quit Session 2 (high): 30 mg/70 kg The abstinent individuals scored significantly higher on a measure of psilocybin-occasioned mystical experience relative to participants still smoking at 6 months 
15-week smoking cessation treatment intervention (CBT and mindfulness training) with two psilocybin session at week 5 and 7 and an optional high third dose at week 13 60% met criteria for “complete” mystical experience which was significantly correlated with smoking cessation outcome 
 Johnson et al. [522017 Retrospective cross-sectional anonymous online survey Psilocybin 38% reported continuous smoking cessation after psychedelic use (Quit group) 
358 individuals who reported having quit or reduced smoking after ingesting a psychedelic in a non-laboratory setting LSD 74.5% of the “Quit group” reported >2 years of abstinence 
Mescaline 28% reported a persisting reduction in smoking (Reduce group) 
DMT/Ayahuasca 62% of the “Reduce group” reported >2 years reduction in smoking 
Dose N/A 34% reported temporary reduction in their smoking before returning to baseline smoking level (Relapse group) 
Participants across all groups reported less severe affective withdrawal symptoms (e.g., depression, craving) after psychedelic use compared with previous quit attempts 
Participants in the “Relapse group” rated the reference psychedelic experience as significantly less personally meaningful than those in the “Quit group” 

CBT, cognitive behavioural therapy; DMT, N, N-dimethyltryptamine; LSD, lysergic acid diethylamide.

Retrospective and prospective online survey studies focussing on classic psychedelics have reported very similar outcomes across alcohol, tobacco, cannabis, opioids, and stimulant addictions. The most common themes included a decrease in withdrawal symptom severity, abstinence, and reduced odds of daily substance use (Table 1, 4, 5) [30, 48, 55‒58]. From association studies, there is evidence that the use of classic psychedelics can reduce the odds of past-year opioid addiction/abuse and cocaine use disorder (Table 2, 6) [47, 59].

Table 5.

Summary of studies using classic and atypical psychedelics in non-ceremonial and ceremonial settings for polydrug use and abuse

SubstanceAuthor(s)YearAddictionStudy characteristicsDrug and doseMain findings
a. Classic psychedelics (psilocybin, LSD, mescaline) Garcia-Romeu et al. [562020 Cannabis use disorder Retrospective cross-sectional online survey study Psilocybin Following the reference psychedelic experience 
Opioid use disorder 444 individuals (cannabis n = 166); opioid n = 123; stimulants n = 155) who met Drug Use Disorders Identification Test-Consumption (DUDIT-C) and DSM-V criteria for their primary drug/class of interest LSD 1. 28% reported less severe withdrawal symptoms, particularly craving compared to prior attempts (56% of cannabis users and 75% of opioid users) 
Stimulant use disorder Moderate to high doses 2. 74.5% greatly reduced or quit using their primary substance (DUDIT-C) 
3. Out of 95.7% substance use disorder (SUD) criteria before the reference psychedelic experience, only 27.3% met SUD criteria in the time since their reference psychedelic experience 
 Agin-Liebes et al. [57] and Uthaug et al. [58] (both utilising the same dataset) 2021 Alcohol use disorder Retrospective naturalistic online survey Mescaline (San Pedro) 48% reported having the most memorable experience 
2022 Drug use disorder 452 participants Moderate to high dose (8–13 h) Participants with previous substance misuse/dependence reported improvement following their most memorable experience 
International epidemiological study Oral self-administration for spiritual and nature connection 1. Alcohol misuse/use disorder = 76% (n = 48) 
2. Drug misuse/use disorder = 68% (n = 58) 
2–5% of participants with psychiatric conditions reported intentions to address/resolve their condition with mescaline 
b. Atypical psychedelics (ibogaine, 5-MeO-DMT) Schenberg et al. [602014 Polydrug abuse Retrospective observational study Ibogaine One treatment of ibogaine led to median of 5.5 months abstinence 
Data from 75 polydrug (alcohol, cannabis, cocaine, crack cocaine) users (DSM-IV) Single dose of Ibogaine HCl: 17 mg/kg Multiple treatments of ibogaine led to median of 8.4 months abstinence 
Combined approach of ibogaine and cognitive behavioural therapy (clinic in Brazil) If weak response to initial dose, they would increase up to 20 mg/kg Both single and multiple ibogaine treatments led to statistically significant longer periods of abstinence than before the first ibogaine treatment 
Option for multiple treatment was available if individuals were experiencing intense craving, relapse, difficulty changing old drug-related habits 
 Davis et al. [612018 Alcohol use disorder Retrospective online survey study 5-MeO-DMT 66% reported improvement in AUD symptoms e.g., craving/desire 
Substance use disorder (non-alcohol) 515 responders Dose N/A 60% reported improvement SUD symptoms e.g., craving/desire 
 Mash et al. [422018 Opioid use disorder Retrospective observational stud of 191 open-label case series Ibogaine Significant decrease in craving symptoms post-treatment and at 1-month follow-up 
Cocaine use disorder Treatment (detoxification) seeking opioid and cocaine dependent (DSM-IV) individuals Ibogaine HCl: 8–12 mg/kg Significant decrease in depression symptoms at 1-month follow-up 
Treatment program also included motivational counselling and referral to aftercare programs and community support groups Decrease in withdrawal symptoms individually (no statistical significance) 
c. Ceremonial psychedelic use (DMT-containing ayahuasca brew) Fábregas et al. [622010 Polydrug abuse 127 ritual jungle- and urban-based ayahuasca users and 115 rural controls (Brazil) Ayahuasca Ritual ayahuasca users relative to controls showed significantly 
Addiction severity was assessed using the ASI Dose N/A 1. Lower ASI Alcohol scores 
2. Lower scores in the Psychiatric Status subscales 
3. Lower drug use (except of cannabis) 
 Thomas et al. [63] (no access to full paper) 2013 Polydrug abuse Observational prospective study Ayahuasca Self-reported alcohol, tobacco and cocaine use declined 
“Working with Addiction and Stress” retreat combined 4 days of group counselling with two expert-led ayahuasca ceremonies Dose N/A Statistically significant reductions in problematic cocaine use 
Twelve polydrug (alcohol, opioids, cocaine, tobacco, cannabis) rural aboriginal population users (Canada)  
 
 Barbosa et al. [642018 Alcohol use disorder Cross-sectional study with ayahuasca users and national normative sample (Brazil) Ayahuasca Alcohol and tobacco use disorder were lower in ritual ayahuasca using UVD members 
Tobacco use disorder 1,947 Uniao do Vegetal (UDV) church members Dose N/A Reduction of alcohol and tobacco use disorder was significantly impacted by 
Alcohol and tobacco use was evaluated through questionnaires first developed by World Health Organisation and the Substance Abuse and Mental Health Services Administration 1. Attendance at ayahuasca ceremonies during the previous 12 months 
2. Years of UDV membership 
SubstanceAuthor(s)YearAddictionStudy characteristicsDrug and doseMain findings
a. Classic psychedelics (psilocybin, LSD, mescaline) Garcia-Romeu et al. [562020 Cannabis use disorder Retrospective cross-sectional online survey study Psilocybin Following the reference psychedelic experience 
Opioid use disorder 444 individuals (cannabis n = 166); opioid n = 123; stimulants n = 155) who met Drug Use Disorders Identification Test-Consumption (DUDIT-C) and DSM-V criteria for their primary drug/class of interest LSD 1. 28% reported less severe withdrawal symptoms, particularly craving compared to prior attempts (56% of cannabis users and 75% of opioid users) 
Stimulant use disorder Moderate to high doses 2. 74.5% greatly reduced or quit using their primary substance (DUDIT-C) 
3. Out of 95.7% substance use disorder (SUD) criteria before the reference psychedelic experience, only 27.3% met SUD criteria in the time since their reference psychedelic experience 
 Agin-Liebes et al. [57] and Uthaug et al. [58] (both utilising the same dataset) 2021 Alcohol use disorder Retrospective naturalistic online survey Mescaline (San Pedro) 48% reported having the most memorable experience 
2022 Drug use disorder 452 participants Moderate to high dose (8–13 h) Participants with previous substance misuse/dependence reported improvement following their most memorable experience 
International epidemiological study Oral self-administration for spiritual and nature connection 1. Alcohol misuse/use disorder = 76% (n = 48) 
2. Drug misuse/use disorder = 68% (n = 58) 
2–5% of participants with psychiatric conditions reported intentions to address/resolve their condition with mescaline 
b. Atypical psychedelics (ibogaine, 5-MeO-DMT) Schenberg et al. [602014 Polydrug abuse Retrospective observational study Ibogaine One treatment of ibogaine led to median of 5.5 months abstinence 
Data from 75 polydrug (alcohol, cannabis, cocaine, crack cocaine) users (DSM-IV) Single dose of Ibogaine HCl: 17 mg/kg Multiple treatments of ibogaine led to median of 8.4 months abstinence 
Combined approach of ibogaine and cognitive behavioural therapy (clinic in Brazil) If weak response to initial dose, they would increase up to 20 mg/kg Both single and multiple ibogaine treatments led to statistically significant longer periods of abstinence than before the first ibogaine treatment 
Option for multiple treatment was available if individuals were experiencing intense craving, relapse, difficulty changing old drug-related habits 
 Davis et al. [612018 Alcohol use disorder Retrospective online survey study 5-MeO-DMT 66% reported improvement in AUD symptoms e.g., craving/desire 
Substance use disorder (non-alcohol) 515 responders Dose N/A 60% reported improvement SUD symptoms e.g., craving/desire 
 Mash et al. [422018 Opioid use disorder Retrospective observational stud of 191 open-label case series Ibogaine Significant decrease in craving symptoms post-treatment and at 1-month follow-up 
Cocaine use disorder Treatment (detoxification) seeking opioid and cocaine dependent (DSM-IV) individuals Ibogaine HCl: 8–12 mg/kg Significant decrease in depression symptoms at 1-month follow-up 
Treatment program also included motivational counselling and referral to aftercare programs and community support groups Decrease in withdrawal symptoms individually (no statistical significance) 
c. Ceremonial psychedelic use (DMT-containing ayahuasca brew) Fábregas et al. [622010 Polydrug abuse 127 ritual jungle- and urban-based ayahuasca users and 115 rural controls (Brazil) Ayahuasca Ritual ayahuasca users relative to controls showed significantly 
Addiction severity was assessed using the ASI Dose N/A 1. Lower ASI Alcohol scores 
2. Lower scores in the Psychiatric Status subscales 
3. Lower drug use (except of cannabis) 
 Thomas et al. [63] (no access to full paper) 2013 Polydrug abuse Observational prospective study Ayahuasca Self-reported alcohol, tobacco and cocaine use declined 
“Working with Addiction and Stress” retreat combined 4 days of group counselling with two expert-led ayahuasca ceremonies Dose N/A Statistically significant reductions in problematic cocaine use 
Twelve polydrug (alcohol, opioids, cocaine, tobacco, cannabis) rural aboriginal population users (Canada)  
 
 Barbosa et al. [642018 Alcohol use disorder Cross-sectional study with ayahuasca users and national normative sample (Brazil) Ayahuasca Alcohol and tobacco use disorder were lower in ritual ayahuasca using UVD members 
Tobacco use disorder 1,947 Uniao do Vegetal (UDV) church members Dose N/A Reduction of alcohol and tobacco use disorder was significantly impacted by 
Alcohol and tobacco use was evaluated through questionnaires first developed by World Health Organisation and the Substance Abuse and Mental Health Services Administration 1. Attendance at ayahuasca ceremonies during the previous 12 months 
2. Years of UDV membership 

ASI, Addiction Severity Index; AUD, alcohol use disorder; DSM, Diagnostic and Statistical Manual of Mental Disorders; DUDIT-C, Drug Use Disorders Identification Test-Consumption; UDV, Uniao do Vegetal (churches); 5-Meo-DMT, O-methyl-bufotenin.

Table 6.

Summary of studies using classic and atypical psychedelics for cocaine use disorder

SubstanceAuthor(s)YearStudy characteristicsDrug and doseMain findings
a. Ketamine Dakwar et al. [652014 Crossover double-blind randomised trial K1: 0.41 mg/kg K1 relative to LZP significantly 
Eight cocaine dependent (DSM-IV) non-treatment and non-abstinence seeking K2: 0.71 mg/kg 1. increased motivation for changing cocaine use 
Three infusions of sub-anaesthetic psychoactive dose of ketamine (K1, K2) or active control lorazepam (LZP) LZP: 2 mg 2. Decreased cue-induced cocaine craving 
K2 further reduced cue-induced craving 
Observed trend in craving reduction following K1 
 Dakwar et al. [662017 Crossover double-blind randomised trial Ketamine HCl: 0.71 mg/kg Ketamine relative to midazolam significantly reduced cocaine self-administration by 67% 
Twenty cocaine dependent (DSM-IV) non-depressed, non-treatment and non-abstinence seeking Midazolam: 0.025 mg/kg Ketamine led to significant reductions in cocaine use and cocaine craving initially, but was not sustained after several days 
Cocaine self-administration paradigm 
Two infusions of sub-aesthetic dose of ketamine or of the active control midazolam 
 Dakwar et al. [672019 Randomised clinical trial Ketamine HCl: 0.5 mg/kg (iv) 48.2% abstinence (last 2 weeks of trial) in the ketamine group compared to 10.7% in the midazolam group 
Fifty-five treatment-seeking cocaine dependent (DSM-IV) individuals Midazolam: 0.025 mg/kg (iv) In the ketamine group compared to the midazolam group 
5-week course of MBRP and were randomly assigned to receive ketamine or active control midazolam during week 1 1. Was 53% less likely to relapse (use cocaine/drop out) 
2. Craving was 58.1% lower 
44% of the ketamine group reported abstinence at 6-month telephone follow-up relative to none of the participants in the midazolam group 
b. Classic psychedelics Jones et al. [592022 Association study Psilocybin Peyote was the only substance associated with lower odds of CUD (decrease by 50%) 
214,505 responders who met CUD criteria and completed the NSDUH from 2015 to 2019 LSD 
Mescaline/peyote 
Dose N/A 
SubstanceAuthor(s)YearStudy characteristicsDrug and doseMain findings
a. Ketamine Dakwar et al. [652014 Crossover double-blind randomised trial K1: 0.41 mg/kg K1 relative to LZP significantly 
Eight cocaine dependent (DSM-IV) non-treatment and non-abstinence seeking K2: 0.71 mg/kg 1. increased motivation for changing cocaine use 
Three infusions of sub-anaesthetic psychoactive dose of ketamine (K1, K2) or active control lorazepam (LZP) LZP: 2 mg 2. Decreased cue-induced cocaine craving 
K2 further reduced cue-induced craving 
Observed trend in craving reduction following K1 
 Dakwar et al. [662017 Crossover double-blind randomised trial Ketamine HCl: 0.71 mg/kg Ketamine relative to midazolam significantly reduced cocaine self-administration by 67% 
Twenty cocaine dependent (DSM-IV) non-depressed, non-treatment and non-abstinence seeking Midazolam: 0.025 mg/kg Ketamine led to significant reductions in cocaine use and cocaine craving initially, but was not sustained after several days 
Cocaine self-administration paradigm 
Two infusions of sub-aesthetic dose of ketamine or of the active control midazolam 
 Dakwar et al. [672019 Randomised clinical trial Ketamine HCl: 0.5 mg/kg (iv) 48.2% abstinence (last 2 weeks of trial) in the ketamine group compared to 10.7% in the midazolam group 
Fifty-five treatment-seeking cocaine dependent (DSM-IV) individuals Midazolam: 0.025 mg/kg (iv) In the ketamine group compared to the midazolam group 
5-week course of MBRP and were randomly assigned to receive ketamine or active control midazolam during week 1 1. Was 53% less likely to relapse (use cocaine/drop out) 
2. Craving was 58.1% lower 
44% of the ketamine group reported abstinence at 6-month telephone follow-up relative to none of the participants in the midazolam group 
b. Classic psychedelics Jones et al. [592022 Association study Psilocybin Peyote was the only substance associated with lower odds of CUD (decrease by 50%) 
214,505 responders who met CUD criteria and completed the NSDUH from 2015 to 2019 LSD 
Mescaline/peyote 
Dose N/A 

CUD, cocaine use disorder; DSM, Diagnostic and Statistical Manual of Mental Disorders; HCl, hydrochloride; LSD, lysergic acid diethylamide; LZP, lorazepam; NSDUH, National Survey on Drug Use and Health; MBRP, mindfulness-based relapse prevention.

Currently, there are also five clinical research projects (clinicaltrials.gov) underway investigating the therapeutic potential of psilocybin for the treatment of cocaine addiction (randomised controlled trial, NCT02037126), methamphetamine addiction (randomised trial, NCT04982796; safety/feasibility, NCT05322954), and opioid-dependent individuals maintained with buprenorphine (double-blind, NCT06067737) or buprenorphine-naloxone formulation (open-label safety, NCT04161066).

Atypical Psychedelics

Out of all the atypical psychedelics, ketamine and ibogaine have been the most popular in the treatment of several addictions including alcohol, opioids, and cocaine (Table 1, 2, 6). Ketamine, a non-competitive NMDA receptor antagonist, was developed and is used worldwide as an anaesthetic and analgesic. In recent years ketamine has re-emerged in the psychiatry world in the form of intranasal esketamine (an optimal isomer of ketamine) spray for the treatment of depression [68, 69]. Krupitsky and colleagues in Russia brought the first significant work using ketamine for addiction treatment in the early 90s [32]. In 1997, Krupitsky and Grinenko conducted a non-randomised study with participants having the freedom to choose between transpersonal ketamine-psychedelic therapy (KPT) or traditional therapy. At 1-year follow-up, 65.8% of the ketamine group was abstinent, compared to 24% of the control group [33]. They proposed that some of the psychological mechanisms of KPT lie in ketamine’s ability to harmonise personality traits and emotional attitudes to self and others and to increase insight and spirituality [33]. Although the study’s results were promising for their time, the study could be subject to selection bias in the treatment allocation. Similar findings were observed by Krupitsky et al. [46] in a much stronger research design of a double-blind active-placebo randomised clinical trial for heroin dependence. Compared to the low ketamine dose control, the high-dose KPT showed greater levels of abstinence at a 2-year follow-up and a longer-lasting reduction in heroin craving.

More recently, clinical trials of ketamine for alcohol and cocaine dependence have built on Krupitsky’s early work, while trying to address methodological limitations by randomly assigning treatment, using pharmacological (active/saline) or psychological placebos, and blinding both the participant and the researchers [35, 36, 38, 65, 66]. Recently ketamine has been paired with mindfulness-based relapse prevention, not only in alcohol addiction [38] but also in cocaine [67] and cannabis [70] addiction. Common effects of this approach across studies showed that ketamine and mindfulness-based relapse prevention increased and sustained abstinence and reduced use and craving.

Maintenance of motivation for sobriety seems to be one of the important proposed psychological mechanisms of ketamine [36, 65]. Depression and addiction are highly comorbid and intertwined, with some studies supporting that ketamine may have downstream effects on neural circuits related to common transdiagnostic factors between depression and addiction like reward sensitivity and anhedonia [36, 38]. Evidence suggests that ketamine promotes downstream signalling pathways that induce neuronal plasticity [71]. Due to ketamine’s ability to sustain over time its therapeutic outcomes, a pro-plasticity and modulatory mechanism of action is also proposed [66]. Lastly, Das et al. [35] propose that the interference of ketamine with memory consolidation may allow the “overwriting of maladaptive drinking memories” and thus its therapeutic effects.

Ibogaine is another psychoactive alkaloid commonly used for the treatment of opioid (Table 2) addiction, mainly due to its unique properties of blocking opiate withdrawal, providing an alternative approach to treatment [72]. Ibogaine is found in the roots of the Tabernanthe iboga plant mainly found in Gabon of occidental equatorial Africa and it has been used for centuries in the Biwiti religious ceremonies and spiritual practices [73]. Alper and colleagues conducted in 1999 an open-label case series study with thirty-three opioid-dependent individuals using ibogaine for opioid detoxification. They found that 76% of the sample showed resolution of opioid withdrawal and drug-seeking behaviour up to 72 h post-infusion [41]. Although there is no evidence of randomised clinical trials for ibogaine, observational studies for opioid addiction have seen a significant reduction in withdrawal symptoms and drug craving and seeking behaviour (Table 2) [42‒45, 72]. In cocaine addiction and polydrug abuse, similar treatment outcomes have been observed, accompanied by long-term abstinence [42, 60]. Aside from the therapeutic dream-like visions that people encounter under the influence of ibogaine [34], it is proposed that the therapeutic benefits of ibogaine are brought from its ability to “suppress the autonomic changes, objective signs, and subjective distress associated with opiate withdrawal” and possibly through its action on the mu-opioid receptors [72]. Although ibogaine appears to have promising treatment effects, especially for opiate dependence, it should be used under appropriate medical supervision, due to its ability to induce QTc prolongation, bradycardia, and severe ataxia, even if the symptoms are reversible [74]. Thus, patients and participants in research studies should undergo thorough physical screenings to ensure their safety.

In 2018, a combination treatment approach with ibogaine and 5-MeO-DMT was used for the treatment of alcohol addiction in a military veteran. 5-MeO-DMT is found on the skin of the Sonoran Desert Toad (Incilius alvarius) and has been used by the Yoeme (Yaqui) people in Sonora [75]. The case study reported alcohol cessation and reduced craving for up to 1-month, with a return to mild alcohol use after 2 months [34]. The release of negative emotions following 5-MeO-DMT use is thought to play a key role in its therapeutic effects [34]. 5-MeO-DMT has also been used for alcohol and substance use disorder with a retrospective online survey study showing that 5-MeO-DMT improved significantly craving and desire to use [61].

MDMA, an atypical psychedelic or entactogen, has been used once for the treatment of addiction, more specifically alcohol. An open-label safety and tolerability study was conducted in Bristol utilising a ten-session recovery-based therapy course assisted by two MDMA sessions (Table 1). At 9 months, the majority were abstinent and those who were not had an average decrease of alcohol units from 131 to 19 [37]. They propose that MDMA’s ability to access emotionally distressing thoughts, images, or memories of alcohol misuse with reduced avoidance while increasing empathy towards the self and others may explain its therapeutic abilities [37]. It may also address symptoms of other comorbid conditions with addiction, like psychological trauma [37, 76].

Psychedelics in a Ceremonial Setting

Psychedelics have a long history of ceremonial and spiritual use among different cultures of the globe. The mescaline-containing peyote cactus (Lophophora williamsii; [77]) has been used for centuries by natives in Mexico and North America [2]. Since 1920, mescaline has become legal to use in religious ceremonies by the Native American Church (NAC) [3]. Albaugh and Anderson in 1974 examined the effectiveness of a treatment program for American Indians to treat their alcohol addiction, which included peyote meetings in the NAC (Table 1). They found that open discussion (“cathartic expression”) about their alcoholism during the NAC ceremonies played a pivotal role in addressing their addiction. They also found that the carry-over effect post peyote ingestion promoted suggestibility and openness to communicate [39]. The vast supportive network and ritual offered by the NAC in synergy with the psychedelic effects of peyote seem to be key components of peyote’s therapeutic effect [78, 79].

Ayahuasca is the DMT-containing brew native to the indigenous communities of the Amazonian rainforest. The two key components of the brew are the DMT-containing leaves of Psychotria viridis and the β-carboline (monoamine oxidase-A inhibitor) containing bark of Banisteriopsis caapi, which is essential to render DMT orally active [80]. According to Miller and colleagues, there is documentation of a ritual bundle containing harmine (β-carboline) and DMT, the primary ingredients of ayahuasca, in the Andean region, dating back 1,000 years ago [81]. In recent years, research has looked into the therapeutic properties of ayahuasca in ceremonial settings. Three cross-sectional studies were conducted in Brazil and one observational prospective study in Canada investigated the therapeutic potential of ayahuasca in a ceremonial/ritualistic setting for drug and alcohol abuse and dependence (Table 1, 5). They found ayahuasca consumption in a ritualistic setting decreased (problematic) drug and alcohol use and addiction severity scores, partly possibly attributed to being part of the church and community [40, 62‒64].

We have a rich history of psychedelic use with Indigenous communities being the gatekeepers of psychedelic plant knowledge, so they should be treated with the uttermost respect. While we move forwards in the 21st century, we should learn from our ancestors’ healing practices and destigmatise the use of psychedelic substances, especially in a therapeutic context. Their consciousness-expanding properties, mystical experiences, and improvement in well-being are some of the therapeutic factors that render psychedelics a promising alternative treatment for addictions, especially for individuals who have failed other conventional treatment approaches. Aside from their psychological effects, they are also able to diminish the physiological responses of addiction recovery, including withdrawal symptoms, craving, and drug-induced responses. Changes in governmental policies and funding across countries like the UK, Canada, and Australia, which recently rescheduled psilocybin and MDMA, making them medically accessible for use in the treatment of treatment-resistant depression and PTSD [82, 83], bring us hope for the future of psychedelic therapeutics for the treatment of addiction and other psychiatric and medical co-occurring disorders.

Ioanna Vamvakopoulou has acted as a paid intern and consultant for Neural Therapeutics with shares. David Nutt’s research group at Imperial College has received research support from the following companies with an interest in the psychedelic space – COMPASS Pathways, Usona, Beckley Psytec, MAPS, and Filament. He also acts as a part-time chief research officer for Awakn Life Sciences a biotech company that is developing novel ketamine and MDMA therapies for addictions and advises Alvarius, Algernon Pharmaceutics, and Neural Therapeutics on their psychedelic research programmes.

This study was not supported by any sponsor or funder.

Ioanna Vamvakopoulou searched and screened the literature and wrote the manuscript. David Nutt reviewed and provided feedback and corrections for the manuscript. All authors read and approved the final manuscript.

1.
Winkelman
M
.
Introduction: evidence for entheogen use in prehistory and world religions
.
J Psychedelic Stud
.
2019
;
3
(
2
):
43
62
.
2.
El-Seedi
HR
,
De Smet
PAGM
,
Beck
O
,
Possnert
G
,
Bruhn
JG
.
Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas
.
J Ethnopharmacol
.
2005
;
101
(
1–3
):
238
42
.
3.
Vamvakopoulou
IA
,
Narine
KAD
,
Campbell
I
,
Dyck
JRB
,
Nutt
DJ
.
Mescaline: the forgotten psychedelic
.
Neuropharmacology
.
2023
;
222
:
109294
.
4.
Heffter
A
.
Ueber cacteenalkaloïde
.
Ber Dtsch Chem Ges
.
1896
;
29
(
1
):
216
27
.
5.
Heffter
A
.
Ueber Pellote. Beiträge zur chemischen undpharmakologischen Kenntniss der Cacteen. II
.
Naunyn-Schmiedeberg’s Arch Pharmacol
.
1898
;
40
(
5–6
):
385
429
.
6.
Yaden
DB
,
Berghella
AP
,
Regier
PS
,
Garcia-Romeu
A
,
Johnson
MW
,
Hendricks
PS
.
Classic psychedelics in the treatment of substance use disorder: potential synergies with twelve-step programs
.
Int J Drug Policy
.
2021
;
98
:
103380
.
7.
Bogenschutz
MP
,
Johnson
MW
.
Classic hallucinogens in the treatment of addictions
.
Prog Neuropsychopharmacol Biol Psychiatry
.
2016
;
64
:
250
8
.
8.
Halberstadt
AL
,
Geyer
MA
.
Serotonergic hallucinogens as translational models relevant to schizophrenia
.
Int J Neuropsychopharmacol
.
2013
;
16
(
10
):
2165
80
.
9.
Halberstadt
AL
,
Geyer
MA
.
Effect of hallucinogens on unconditioned behavior
.
Curr Top Behav Neurosci
.
2018
;
36
:
159
99
.
10.
Halberstadt
AL
,
Powell
SB
,
Geyer
MA
.
Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice
.
Neuropharmacology
.
2013
;
70
:
218
27
.
11.
Preller
KH
,
Herdener
M
,
Pokorny
T
,
Planzer
A
,
Kraehenmann
R
,
Stämpfli
P
, et al
.
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation
.
Curr Biol
.
2017
;
27
(
3
):
451
7
.
12.
Nichols
DE
,
Nichols
CD
.
The pharmacology of psychedelics
. In:
Handbook of medical hallucinogens
.
New York, NY
:
The Guilford Press
;
2021
; p.
3
28
.
13.
Rickli
A
,
Moning
OD
,
Hoener
MC
,
Liechti
ME
.
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
.
Eur Neuropsychopharmacol
.
2016
;
26
(
8
):
1327
37
.
14.
Anis
N
,
Berry
S
,
Burton
N
,
Lodge
D
.
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
.
Br J Pharmacol
.
1983
;
79
(
2
):
565
75
.
15.
Glick
SD
,
Maisonneuve
IM
,
Szumlinski
KK
.
18‐Methoxycoronaridine (18‐MC) and Ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action
.
Ann N Y Acad Sci
.
2000
;
914
(
1
):
369
86
.
16.
Wasko
MJ
,
Witt-Enderby
PA
,
Surratt
CK
.
DARK classics in chemical neuroscience: ibogaine
.
ACS Chem Neurosci
.
2018
;
9
(
10
):
2475
83
.
17.
Zanos
P
,
Moaddel
R
,
Morris
PJ
,
Riggs
LM
,
Highland
JN
,
Georgiou
P
, et al
.
Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms
.
Pharmacol Rev
.
2018
;
70
(
3
):
621
60
.
18.
Dumont
GJ
,
Sweep
F
,
Van der Steen
R
,
Hermsen
R
,
Donders
A
,
Touw
DJ
, et al
.
Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3, 4-methylenedioxymethamphetamine) administration
.
Soc Neurosci
.
2009
;
4
(
4
):
359
66
.
19.
Krebs-Thomson
K
,
Ruiz
EM
,
Masten
V
,
Buell
M
,
Geyer
MA
.
The roles of 5-HT 1A and 5-HT 2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats
.
Psychopharmacology
.
2006
;
189
(
3
):
319
29
.
20.
Schlag
AK
,
Aday
J
,
Salam
I
,
Neill
JC
,
Nutt
DJ
.
Adverse effects of psychedelics: from anecdotes and misinformation to systematic science
.
J Psychopharmacol
.
2022
;
36
(
3
):
258
72
.
21.
Guttmann
E
.
Artificial psychoses produced by mescaline
.
J Ment Sci
.
1936
;
82
(
338
):
203
21
.
22.
Cumming
P
,
Scheidegger
M
,
Dornbierer
D
,
Palner
M
,
Quednow
BB
,
Martin-Soelch
C
.
Molecular and functional imaging studies of psychedelic drug action in animals and humans
.
Molecules
.
2021
;
26
(
9
):
2451
.
23.
Pahnke
WN
.
Drugs and mysticism
.
Int J Parapsychol
.
1966
;
8
(
2
):
295
313
.
24.
Pahnke
WN
.
The psychedelic mystical experience in the human encounter with death
.
Harv Theol Rev
.
1969
;
62
(
1
):
1
21
.
25.
Zafar
R
,
Siegel
M
,
Harding
R
,
Barba
T
,
Agnorelli
C
,
Suseelan
S
, et al
.
Psychedelic therapy in the treatment of addiction: the past, present and future
.
Front Psychiatry
.
2023
;
14
:
1183740
.
26.
Dyck
E
.
Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950–1970
.
Soc Hist Med
.
2006
;
19
(
2
):
313
29
.
27.
Krebs
TS
,
Johansen
P-Ø
.
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
.
J Psychopharmacol
.
2012
;
26
(
7
):
994
1002
.
28.
Savage
C
,
McCabe
OL
.
Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study
.
Arch Gen Psychiatry
.
1973
;
28
(
6
):
808
14
.
29.
Bogenschutz
MP
,
Forcehimes
AA
,
Pommy
JA
,
Wilcox
CE
,
Barbosa
PCR
,
Strassman
RJ
.
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
.
J Psychopharmacol
.
2015
;
29
(
3
):
289
99
.
30.
Garcia-Romeu
A
,
Davis
AK
,
Erowid
F
,
Erowid
E
,
Griffiths
RR
,
Johnson
MW
.
Cessation and reduction in alcohol consumption and misuse after psychedelic use
.
J Psychopharmacol
.
2019
;
33
(
9
):
1088
101
.
31.
Bogenschutz
MP
,
Ross
S
,
Bhatt
S
,
Baron
T
,
Forcehimes
AA
,
Laska
E
, et al
.
Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial
.
JAMA Psychiatry
.
2022
;
79
(
10
):
953
62
.
32.
Krupitsky
EM
,
Grineko
AY
,
Berkaliev
TN
,
Paley
AI
,
Tetrov
UN
,
Mushkov
KA
, et al
.
The combination of psychedelic and aversive approaches in alcoholism treatment
.
Alcohol Treat Q
.
1992
;
9
(
1
):
99
105
.
33.
Krupitsky
EM
,
Grinenko
AY
.
Ketamine psychedelic therapy (KPT): a review of the results of ten years of research
.
J Psychoactive Drugs
.
1997
;
29
(
2
):
165
83
.
34.
Barsuglia
JP
,
Polanco
M
,
Palmer
R
,
Malcolm
BJ
,
Kelmendi
B
,
Calvey
T
.
Chapter 5: a case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
. In:
Calvey
T
, editor.
Progress in brain research
.
Elsevier
;
2018
. p.
121
58
.
35.
Das
RK
,
Gale
G
,
Walsh
K
,
Hennessy
VE
,
Iskandar
G
,
Mordecai
LA
, et al
.
Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories
.
Nat Commun
.
2019
;
10
(
1
):
5187
.
36.
Dakwar
E
,
Levin
F
,
Hart
CL
,
Basaraba
C
,
Choi
J
,
Pavlicova
M
, et al
.
A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial
.
Am J Psychiatry
.
2020
;
177
(
2
):
125
33
.
37.
Sessa
B
,
Higbed
L
,
O’Brien
S
,
Durant
C
,
Sakal
C
,
Titheradge
D
, et al
.
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder
.
J Psychopharmacol
.
2021
;
35
(
4
):
375
83
.
38.
Grabski
M
,
McAndrew
A
,
Lawn
W
,
Marsh
B
,
Raymen
L
,
Stevens
T
, et al
.
Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder
.
Am J Psychiatry
.
2022
;
179
(
2
):
152
62
.
39.
Albaugh
BJ
,
Anderson
PO
.
Peyote in the treatment of alcoholism among American Indians
.
Am J Psychiatry
.
1974
;
131
(
11
):
1247
50
.
40.
Doering-Silveira
E
,
Grob
CS
,
de Rios
MD
,
Lopez
E
,
Alonso
LK
,
Tacla
C
, et al
.
Report on psychoactive drug use among adolescents using ayahuasca within a religious context
.
J Psychoactive Drugs
.
2005
;
37
(
2
):
141
4
.
41.
Alper
KR
,
Lotsof
HS
,
Frenken
GMN
,
Luciano
DJ
,
Bastiaans
J
.
Treatment of acute opioid withdrawal with ibogaine
.
Am J Addict
.
1999
;
8
(
3
):
234
42
.
42.
Mash
DC
,
Duque
L
,
Page
B
,
Allen-Ferdinand
K
.
Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes
.
Front Pharmacol
.
2018
;
9
:
529
.
43.
Noller
GE
,
Frampton
CM
,
Yazar-Klosinski
B
.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
.
Am J Drug Alcohol Abuse
.
2018
;
44
(
1
):
37
46
.
44.
Brown
TK
,
Alper
K
.
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
.
Am J Drug Alcohol Abuse
.
2018
;
44
(
1
):
24
36
.
45.
Malcolm
BJ
,
Polanco
M
,
Barsuglia
JP
.
Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine
.
J Psychoactive Drugs
.
2018
;
50
(
3
):
256
65
.
46.
Krupitsky
E
,
Burakov
A
,
Romanova
T
,
Dunaevsky
I
,
Strassman
R
,
Grinenko
A
.
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
.
J Subst Abuse Treat
.
2002
;
23
(
4
):
273
83
.
47.
Pisano
VD
,
Putnam
NP
,
Kramer
HM
,
Franciotti
KJ
,
Halpern
JH
,
Holden
SC
.
The association of psychedelic use and opioid use disorders among illicit users in the United States
.
J Psychopharmacol
.
2017
;
31
(
5
):
606
13
.
48.
Argento
E
,
Socias
ME
,
Hayashi
K
,
Choi
J
,
Mackay
L
,
Christie
D
, et al
.
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
.
Int J Drug Policy
.
2022
;
100
:
103518
.
49.
Andersson
C
,
Kristinsson
J
,
Gry
J
.
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
.
Nordic Council of Ministers
;
2009
.
50.
Guzmán
G
.
Hallucinogenic mushrooms in Mexico: an overview
.
Econ Bot
.
2008
;
62
(
3
):
404
12
.
51.
Johnson
MW
,
Garcia-Romeu
A
,
Cosimano
MP
,
Griffiths
RR
.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
.
J Psychopharmacol
.
2014
;
28
(
11
):
983
92
.
52.
Johnson
MW
,
Garcia-Romeu
A
,
Griffiths
RR
.
Long-term follow-up of psilocybin-facilitated smoking cessation
.
Am J Drug Alcohol Abuse
.
2017
;
43
(
1
):
55
60
.
53.
Garcia-Romeu
A
,
Griffiths
R
,
Johnson
M
.
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction
.
Curr Drug Abuse Rev
.
2014
;
7
(
3
):
157
64
.
54.
Koob
GF
,
Volkow
ND
.
Neurocircuitry of addiction
.
Neuropsychopharmacology
.
2010
;
35
(
1
):
217
38
.
55.
Johnson
MW
,
Garcia-Romeu
A
,
Johnson
PS
,
Griffiths
RR
.
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
.
J Psychopharmacol
.
2017
;
31
(
7
):
841
50
.
56.
Garcia-Romeu
A
,
Davis
AK
,
Erowid
E
,
Erowid
F
,
Griffiths
RR
,
Johnson
MW
.
Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey
.
Front Psychiatry
.
2019
;
10
:
955
.
57.
Agin-Liebes
G
,
Haas
TF
,
Lancelotta
R
,
Uthaug
MV
,
Ramaekers
JG
,
Davis
AK
.
Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes
.
ACS Pharmacol Transl Sci
.
2021
;
4
(
2
):
543
52
.
58.
Uthaug
MV
,
Davis
AK
,
Haas
TF
,
Davis
D
,
Dolan
SB
,
Lancelotta
R
, et al
.
The epidemiology of mescaline use: pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
.
J Psychopharmacol
.
2022
;
36
(
3
):
309
20
.
59.
Jones
GM
,
Nock
MK
.
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
.
Sci Rep
.
2022
;
12
(
1
):
2574
.
60.
Schenberg
EE
,
de Castro Comis
MA
,
Chaves
BR
,
da Silveira
DX
.
Treating drug dependence with the aid of ibogaine: a retrospective study
.
J Psychopharmacol
.
2014
;
28
(
11
):
993
1000
.
61.
Davis
AK
,
Barsuglia
JP
,
Lancelotta
R
,
Grant
RM
,
Renn
E
.
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption
.
J Psychopharmacol
.
2018
;
32
(
7
):
779
92
.
62.
Fábregas
JM
,
González
D
,
Fondevila
S
,
Cutchet
M
,
Fernández
X
,
Barbosa
PCR
, et al
.
Assessment of addiction severity among ritual users of ayahuasca
.
Drug Alcohol Depend
.
2010
;
111
(
3
):
257
61
.
63.
Thomas
G
,
Lucas
P
,
Capler
NR
,
Tupper
KW
,
Martin
G
.
Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada
.
Curr Drug Abuse Rev
.
2013
;
6
(
1
):
30
42
.
64.
Barbosa
PCR
,
Tófoli
LF
,
Bogenschutz
MP
,
Hoy
R
,
Berro
LF
,
Marinho
EAV
, et al
.
Assessment of alcohol and tobacco use disorders among religious users of ayahuasca
.
Front Psychiatry
.
2018
;
9
:
136
.
65.
Dakwar
E
,
Levin
F
,
Foltin
RW
,
Nunes
EV
,
Hart
CL
.
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers
.
Biol Psychiatry
.
2014
;
76
(
1
):
40
6
.
66.
Dakwar
E
,
Hart
CL
,
Levin
FR
,
Nunes
EV
,
Foltin
RW
.
Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial
.
Mol Psychiatry
.
2017
;
22
(
1
):
76
81
.
67.
Dakwar
E
,
Nunes
EV
,
Hart
CL
,
Foltin
RW
,
Mathew
SJ
,
Carpenter
KM
, et al
.
A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial
.
Am J Psychiatry
.
2019
;
176
(
11
):
923
30
.
68.
Berman
RM
,
Cappiello
A
,
Anand
A
,
Oren
DA
,
Heninger
GR
,
Charney
DS
, et al
.
Antidepressant effects of ketamine in depressed patients
.
Biol Psychiatry
.
2000
;
47
(
4
):
351
4
.
69.
Walsh
Z
,
Mollaahmetoglu
OM
,
Rootman
J
,
Golsof
S
,
Keeler
J
,
Marsh
B
, et al
.
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
.
BJPsych Open
.
2021
;
8
(
1
):
e19
.
70.
Azhari
N
,
Hu
H
,
O’Malley
KY
,
Blocker
ME
,
Levin
FR
,
Dakwar
E
.
Ketamine-facilitated behavioral treatment for cannabis use disorder: a proof of concept study
.
Am J Drug Alcohol Abuse
.
2021
;
47
(
1
):
92
7
.
71.
Aleksandrova
LR
,
Phillips
AG
.
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
.
Trends Pharmacol Sci
.
2021
;
42
(
11
):
929
42
.
72.
Mash
DC
,
Kovera
CA
,
Pablo
J
,
Tyndale
R
,
Ervin
FR
,
Kamlet
JD
, et al
.
Chapter 8 Ibogaine in the treatment of heroin withdrawal
. In:
The alkaloids: chemistry and biology
.
Academic Press
;
2001
; p.
155
71
.
73.
Samorini
G
.
The Bwiti religion and the psychoactive plant Tabernanthe iboga (Equatorial Africa)
.
Integration
.
1995
;
5
:
105
14
.
74.
Knuijver
T
,
Schellekens
A
,
Belgers
M
,
Donders
R
,
van Oosteren
T
,
Kramers
K
, et al
.
Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study
.
Addiction
.
2022
;
117
(
1
):
118
28
.
75.
Villa
RA
.
Toad in the road: biocultural history and conservation challenges of the Sonoran Desert Toad
.
J Psychedelic Stud
.
2023
;
7
(
S1
):
68
79
.
76.
Nicholas
CR
,
Wang
JB
,
Coker
A
,
Mitchell
JM
,
Klaire
SS
,
Yazar-Klosinski
B
, et al
.
The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD
.
Drug Alcohol Depend
.
2022
;
233
:
109356
.
77.
Cassels
BK
,
Sáez-Briones
P
.
Dark classics in chemical neuroscience: mescaline
.
ACS Chem Neurosci
.
2018
;
9
(
10
):
2448
58
.
78.
Blum
K
,
Futterman
SL
,
Pascarosa
P
.
Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale
.
Clin Toxicol
.
1977
;
11
(
4
):
459
72
.
79.
Prue
B
.
Indigenous supports for recovery from alcoholism and drug abuse: the native American church
.
J Ethn Cult Divers Soc Work
.
2013
;
22
(
3–4
):
271
87
.
80.
McKenna
DJ
.
Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges
.
Pharmacol Ther
.
2004
;
102
(
2
):
111
29
.
81.
Miller
MJ
,
Albarracin-Jordan
J
,
Moore
C
,
Capriles
JM
.
Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America
.
Proc Natl Acad Sci U S A
.
2019
;
116
(
23
):
11207
12
.
82.
Barnett
BS
,
Parker
SE
,
Weleff
J
.
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
.
Int J Drug Policy
.
2022
;
99
:
103473
.
83.
Dixon Ritchie
O
,
Donley
CN
,
Dixon Ritchie
G
.
From prohibited to prescribed: the rescheduling of MDMA and psilocybin in Australia
.
Drug Sci Policy L
.
2023
;
9
:
20503245231198472
.